Earnings Call · Q2 FY2021·2021-08-09

Q2 21EPS -38.10%·Rev n/aQ1 21EPS -38.10%·Rev n/aQ4 20EPS -100.00%*·Rev n/aQ3 20EPS +24.00%·Rev n/a⚠ consensus missing

OCULAR THERAPEUTIX, INC OCUL

Donald Notman — Chief Financial Officer

Antony Mattessich — Chief Executive Officer

Dr. Michael Goldstein — Chief Medical Officer

+1.9%1d on move date+2.0% vs SPY3d+4.4%5d+2.2%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more OCUL calls or request research access.

More OCUL calls Browse calls Request research access